NCCN Guidelines Updated to Include PSMA-PET Imaging
Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes PSMA PET imaging modalities, including Ga-68…
Read moreNews & Views
FDA Approves Phase II Kidney Cancer Therapy Study
Telix announces the FDA has accepted the IND Application to undertake a clinical study of Telix’s investigational kidney cancer therapy,…
Read more
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
Telix enters a commercial distribution agreement with Radius for Telix’s prostate cancer investigational imaging product…
Read more
Telix In-Licences Novel Tumour Microenvironment PET Tracer
Telix announces an exclusive licence agreement for a novel PET radiotracer originating from the Université catholique de…
Read more
Japanese Prostate Cancer Imaging Study Completes Enrolment
Telix has completed a Phase I clinical trial of TLX591-CDx for prostate cancer imaging in Japan in collaboration with Kanazawa…
Read more
Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics
Telix announces collaboration with Kettering Health on PSMA-targeting…
Read more
Michael Didocha Joins Telix as Chief Financial Officer, Americas
Telix is delighted to announce the appointment of Michael Didocha as Chief Financial Officer for the Americas…
Read more
Samantha McSherry Joins Telix as Director of Commercial Operations ANZ
Telix is delighted to announce that Samantha McSherry has joined Telix as Director of Commercial Operations for Australia and New…
Read more
Telix and Lightpoint Medical to Collaborate on Radioguided Surgery
Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI® in radioguided surgery…
Read more
Half Year Shareholder Update
Telix Pharmaceuticals Limited Announces Half-year Shareholder…
Read more